Drugs giant AstraZeneca has admitted that the formulation patent protecting its Seroquel XR product was deemed invalid by the High Court in the UK.
The patent was challenged by Accord Healthcare, Intas Pharmaceuticals, Hexal AG and Sandoz, Teva UK, and Teva Pharmaceutical Industries.
Astra assured that this decision is limited only to the UK market and is not binding in other countries. The District Court in The Hague, Netherlands, already found the formulation patent to be valid. Decisions from trials in the US and Spain are pending.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
AstraZeneca said it is "disappointed" with the court's decision and added that the company remains committed to defending its intellectual property protecting Seroquel XR.
Shares were down 0.26% to 2,844.00p.
NR
-
8 of the best houses for sale with annexesThe best houses with annexes – from a period property in the Lake District to a 13th-century house with a two-bedroom annexe in Saltwood, Kent
-
Zelenskyy moves to appease Donald Trump – what happens now?Ukraine’s president Volodymyr Zelenskyy is conceding ground to secure the least-worst deal possible, says Emily Hohler
